Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two leaders in the CGM space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing […]
Legal News
BD to pay SEC $175M to settle Alaris investigation
BD (NYSE:BDX) announced that it reached an agreement with the SEC to resolve an investigation related to its Alaris system. The investigation relates to prior public disclosures and SEC reporting regarding Alaris, an infusion pump system. BD neither admits nor denies the findings of an SEC order related to those matters occurring more than four years […]
European court rules in favor of Abbott in Dexcom CGM patent spat
The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim from Dexcom (Nasdaq:DXCM). Abbott and Dexcom are two leaders in the continuous glucose monitoring (CGM) space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing their latest-generation technologies. Dexcom requested that the court find infringement […]
Insulet prevails in IP battle with patch pump maker EOFlow
Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court. Both companies develop automated insulin delivery systems utilizing patch pump technology. Insulet offers the market-leading Omnipod platform, while Korea-based EOFlow develops the EOPatch — similarly, a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point […]
Class action suit targets Abbott FreeStyle Libre amid claims of data sharing
Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre platform. ClassAction.org first reported on the claims. The lawsuit alleges that tracking tools on Abbott’s FreeStyle Libre website expose private consumer information without their knowledge or consent. Its FreeStyle.Abbott website provides educational tools for the continuous glucose […]
Former Medtronic acquisition target EOFlow to raise $61.5M, faces Insulet patent infringement lawsuit
EOFlow faces a patent infringement lawsuit from fellow insulin patch pump maker Insulet as it attempts to bring in millions in a new funding round. The Korea-based company develops the EOPatch — a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point set to be acquired by Medtronic for $738 million last […]
Report: Court says SiBio can’t sell CGM in some European countries amid Abbott IP battle
JUVE-Patent reports that The Hague recently handed down two new decisions in a CGM patent battle between Abbott and SiBio. One case saw an Abbott patent infringement application shot down, while the other granted the U.S. medtech giant’s claim. The granted one could mean SiBio can’t distribute its CGMs in Germany, France, the Netherlands and […]
Dexcom, Abbott ask for another trial in CGM patent spat
Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) both submitted legal briefs angling for another trial in an ongoing continuous glucose monitor (CGM) patent spat. In March, the U.S. District Court for the District of Delaware found that Dexcom violated a single patent belonging to Abbott and its FreeStyle Libre sensors. However, the court found that Dexcom did […]
Report: Abbott files trio of patent lawsuits over CGM tech in Europe
Abbott (NYSE:ABT) filed three patent lawsuits against SiBionics and its distribution partner in Europe, JUVE-Patent reports. The lawsuits include patent infringement allegations centered around continuous glucose monitoring (CGM) devices, according to the report. Abbott filed them against China-based SiBionics and its sales partner Umedwings at the Unified Patent Court. SiBionics develops, manufactures and distributes CGM […]
Report: Insulet trumps Medtrum again in French patent spat
JUVE-Patent reports that the Judicial Court of Paris again ruled in favor of Insulet (Nasdaq:PODD) in its patent battle with Medtrum. According to the report, the court sided with Insulet in a case regarding the company’s patent (EP 1 874 390). The ruling finds that Medtrum’s A6 and A7+ TouchCare insulin pump devices infringe the valid […]
